These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 24521424)

  • 1. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.
    Stohl W
    Expert Opin Ther Targets; 2014 Apr; 18(4):473-89. PubMed ID: 24521424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).
    Stohl W
    Expert Rev Clin Immunol; 2017 Jun; 13(6):623-633. PubMed ID: 28164726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
    Lenert A; Lenert P
    Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the BLyS-APRIL signaling pathway in SLE.
    La Cava A
    Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rationale for BAFF inhibition in systemic lupus erythematosus.
    Davidson A
    Curr Rheumatol Rep; 2012 Aug; 14(4):295-302. PubMed ID: 22535567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
    Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
    Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab.
    Kowalczyk-Quintas C; Chevalley D; Willen L; Jandus C; Vigolo M; Schneider P
    Front Immunol; 2018; 9():2698. PubMed ID: 30524439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.
    Samy E; Wax S; Huard B; Hess H; Schneider P
    Int Rev Immunol; 2017 Jan; 36(1):3-19. PubMed ID: 28215100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BAFF inhibition in SLE-Is tolerance restored?
    Jackson SW; Davidson A
    Immunol Rev; 2019 Nov; 292(1):102-119. PubMed ID: 31562657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.
    Haselmayer P; Vigolo M; Nys J; Schneider P; Hess H
    Eur J Immunol; 2017 Jun; 47(6):1075-1085. PubMed ID: 28383107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.
    Salazar-Camarena DC; Ortiz-Lazareno PC; Cruz A; Oregon-Romero E; Machado-Contreras JR; Muñoz-Valle JF; Orozco-López M; Marín-Rosales M; Palafox-Sánchez CA
    Lupus; 2016 May; 25(6):582-92. PubMed ID: 26424128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date.
    Lenert A; Niewold TB; Lenert P
    Drug Des Devel Ther; 2017; 11():747-757. PubMed ID: 28331294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers.
    Figgett WA; Deliyanti D; Fairfax KA; Quah PS; Wilkinson-Berka JL; Mackay F
    J Autoimmun; 2015 Jul; 61():9-16. PubMed ID: 26027434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAFF and selection of autoreactive B cells.
    Liu Z; Davidson A
    Trends Immunol; 2011 Aug; 32(8):388-94. PubMed ID: 21752714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus.
    Jordan N; Lutalo PM; D'Cruz DP
    Immunotherapy; 2015; 7(3):255-70. PubMed ID: 25804478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus.
    Martin J; Cheng Q; Laurent SA; Thaler FS; Beenken AE; Meinl E; Krönke G; Hiepe F; Alexander T
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39409173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity.
    Vincent FB; Saulep-Easton D; Figgett WA; Fairfax KA; Mackay F
    Cytokine Growth Factor Rev; 2013 Jun; 24(3):203-15. PubMed ID: 23684423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
    Shin W; Lee HT; Lim H; Lee SH; Son JY; Lee JU; Yoo KY; Ryu SE; Rhie J; Lee JY; Heo YS
    Nat Commun; 2018 Mar; 9(1):1200. PubMed ID: 29572471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
    Mosak J; Furie R
    Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.